Amylyx Pharmaceuticals’ recently approved Relyvrio, an amyotrophic lateral sclerosis drug that’s priced at $158,000 for an annual supply, is the latest example of drugmakers inflating medication costs, critics told The Wall Street Journal.
Read the full post on Becker's Hospital Review - Healthcare News
